Fibrocell Science (NASDAQ:FCSC)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research note issued on Thursday, March 28th, AnalystRatings.com reports. They presently have a $22.00 target price on the stock.
The analysts wrote, “Valuation and risks to price target achievement. We reiterate our Buy rating and $22 price target. We point out that the large delta between the current share price and our price target is driven by the company’s relatively low share count. Further, we believe that the current share price does not reflect, despite the low patient numbers, the ability of FCX-007 to address RDEB patients’ needs, as well as the accelerated potential from a regulatory standpoint, including a Priority Review Voucher (PRV).””
Other research analysts have also recently issued research reports about the company. Zacks Investment Research cut Fibrocell Science from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 15th. ValuEngine cut Fibrocell Science from a “hold” rating to a “sell” rating in a report on Monday, December 17th.
Fibrocell Science (NASDAQ:FCSC) last announced its quarterly earnings results on Wednesday, March 27th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.48. Analysts forecast that Fibrocell Science will post -1.15 EPS for the current year.
An institutional investor recently raised its position in Fibrocell Science stock. Virtu Financial LLC raised its holdings in Fibrocell Science Inc (NASDAQ:FCSC) by 90.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,864 shares of the company’s stock after buying an additional 18,958 shares during the quarter. Virtu Financial LLC owned approximately 0.41% of Fibrocell Science worth $77,000 at the end of the most recent quarter. 27.75% of the stock is owned by hedge funds and other institutional investors.
Fibrocell Science Company Profile
Fibrocell Science, Inc, an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.
See Also: Systematic Risk
Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.